207 related articles for article (PubMed ID: 35621629)
1. Non-Mutated Nucleophosmin 1 Is Recognized by the CD8+ T Lymphocytes of an AML Patient after the Transplantation of Hematopoietic Stem Cells from an HLA-Haploidentical Donor.
Nemeckova S; Alexova-Zurkova K; Hainz P; Krystofova J; Mackova J; Roubalova K; Stastna-Markova M; Vrana M; Vydra J
Curr Oncol; 2022 Apr; 29(5):2928-2934. PubMed ID: 35621629
[TBL] [Abstract][Full Text] [Related]
2. Imidazoquinoxaline derivative EAPB0503: A promising drug targeting mutant nucleophosmin 1 in acute myeloid leukemia.
Nabbouh AI; Hleihel RS; Saliba JL; Karam MM; Hamie MH; Wu HJM; Berthier CP; Tawil NM; Bonnet PA; Deleuze-Masquefa C; El Hajj HA
Cancer; 2017 May; 123(9):1662-1673. PubMed ID: 28055106
[TBL] [Abstract][Full Text] [Related]
3. EAPB0503, an Imidazoquinoxaline Derivative Modulates SENP3/ARF Mediated SUMOylation, and Induces NPM1c Degradation in NPM1 Mutant AML.
Skayneh H; Jishi B; Hleihel R; Hamie M; El Hajj R; Deleuze-Masquefa C; Bonnet PA; El Sabban M; El Hajj H
Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35408798
[TBL] [Abstract][Full Text] [Related]
4. NPM1-mutated acute myeloid leukemia: New pathogenetic and therapeutic insights and open questions.
Falini B
Am J Hematol; 2023 Sep; 98(9):1452-1464. PubMed ID: 37317978
[TBL] [Abstract][Full Text] [Related]
5. Altered nucleophosmin transport in acute myeloid leukaemia with mutated NPM1: molecular basis and clinical implications.
Falini B; Bolli N; Liso A; Martelli MP; Mannucci R; Pileri S; Nicoletti I
Leukemia; 2009 Oct; 23(10):1731-43. PubMed ID: 19516275
[TBL] [Abstract][Full Text] [Related]
6. Allogeneic stem-cell transplantation in patients with NPM1-mutated acute myeloid leukemia: results from a prospective donor versus no-donor analysis of patients after upfront HLA typing within the SAL-AML 2003 trial.
Röllig C; Bornhäuser M; Kramer M; Thiede C; Ho AD; Krämer A; Schäfer-Eckart K; Wandt H; Hänel M; Einsele H; Aulitzky WE; Schmitz N; Berdel WE; Stelljes M; Müller-Tidow C; Krug U; Platzbecker U; Wermke M; Baldus CD; Krause SW; Stölzel F; von Bonin M; Schaich M; Serve H; Schetelig J; Ehninger G
J Clin Oncol; 2015 Feb; 33(5):403-10. PubMed ID: 25547501
[TBL] [Abstract][Full Text] [Related]
7. Small molecules enhancers of amyloid aggregation of C-terminal domain of Nucleophosmin 1 in acute myeloid leukemia.
Florio D; Roviello V; La Manna S; Napolitano F; Maria Malfitano A; Marasco D
Bioorg Chem; 2022 Oct; 127():106001. PubMed ID: 35803020
[TBL] [Abstract][Full Text] [Related]
8. Mutant NPM1 Directly Regulates Oncogenic Transcription in Acute Myeloid Leukemia.
Uckelmann HJ; Haarer EL; Takeda R; Wong EM; Hatton C; Marinaccio C; Perner F; Rajput M; Antonissen NJC; Wen Y; Yang L; Brunetti L; Chen CW; Armstrong SA
Cancer Discov; 2023 Mar; 13(3):746-765. PubMed ID: 36455613
[TBL] [Abstract][Full Text] [Related]
9. Impact of FLT3 internal tandem duplication and NPM1 mutations in acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation.
Khanolkar RA; Faridi RM; Kinzel M; Jamani K; Savoie ML; Shafey M; Khan FM; Storek J
Cytotherapy; 2022 Apr; 24(4):413-420. PubMed ID: 34863627
[TBL] [Abstract][Full Text] [Related]
10. HLA Class I Genotype Is Associated with Relapse Risk after Allogeneic Stem Cell Transplantation for NPM1-Mutated Acute Myeloid Leukemia.
Narayan R; Niroula A; Wang T; Kuxhausen M; He M; Meyer E; Chen YB; Bhatt VR; Beitinjaneh A; Nishihori T; Sharma A; Brown VI; Kamoun M; Diaz MA; Abid MB; Askar M; Kanakry CG; Gragert L; Bolon YT; Marsh SGE; Gadalla SM; Paczesny S; Spellman S; Lee SJ
Transplant Cell Ther; 2023 Jul; 29(7):452.e1-452.e11. PubMed ID: 36997024
[TBL] [Abstract][Full Text] [Related]
11. Functional regulation of the apurinic/apyrimidinic endonuclease 1 by nucleophosmin: impact on tumor biology.
Vascotto C; Lirussi L; Poletto M; Tiribelli M; Damiani D; Fabbro D; Damante G; Demple B; Colombo E; Tell G
Oncogene; 2014 May; 33(22):2876-87. PubMed ID: 23831574
[TBL] [Abstract][Full Text] [Related]
12. Nucleophosmin 1: from its pathogenic role to a tantalizing therapeutic target in acute myeloid leukemia.
Shi Y; Xue Y; Wang C; Yu L
Hematology; 2022 Dec; 27(1):609-619. PubMed ID: 35621728
[TBL] [Abstract][Full Text] [Related]
13. Mutated regions of nucleophosmin 1 elicit both CD4(+) and CD8(+) T-cell responses in patients with acute myeloid leukemia.
Greiner J; Ono Y; Hofmann S; Schmitt A; Mehring E; Götz M; Guillaume P; Döhner K; Mytilineos J; Döhner H; Schmitt M
Blood; 2012 Aug; 120(6):1282-9. PubMed ID: 22592607
[TBL] [Abstract][Full Text] [Related]
14. The effect of small molecule inhibitor NSC348884 on nucleophosmin 1-mutated acute myeloid leukemia cells.
Zhu JF; Han LL; Ma Y; Wang YX; Zhang F
Eur Rev Med Pharmacol Sci; 2023 Oct; 27(19):9145-9151. PubMed ID: 37843328
[TBL] [Abstract][Full Text] [Related]
15. Mutant NPM1 Hijacks Transcriptional Hubs to Maintain Pathogenic Gene Programs in Acute Myeloid Leukemia.
Wang XQD; Fan D; Han Q; Liu Y; Miao H; Wang X; Li Q; Chen D; Gore H; Himadewi P; Pfeifer GP; Cierpicki T; Grembecka J; Su J; Chong S; Wan L; Zhang X
Cancer Discov; 2023 Mar; 13(3):724-745. PubMed ID: 36455589
[TBL] [Abstract][Full Text] [Related]
16. CD34+ cells from AML with mutated NPM1 harbor cytoplasmic mutated nucleophosmin and generate leukemia in immunocompromised mice.
Martelli MP; Pettirossi V; Thiede C; Bonifacio E; Mezzasoma F; Cecchini D; Pacini R; Tabarrini A; Ciurnelli R; Gionfriddo I; Manes N; Rossi R; Giunchi L; Oelschlägel U; Brunetti L; Gemei M; Delia M; Specchia G; Liso A; Di Ianni M; Di Raimondo F; Falzetti F; Del Vecchio L; Martelli MF; Falini B
Blood; 2010 Nov; 116(19):3907-22. PubMed ID: 20634376
[TBL] [Abstract][Full Text] [Related]
17. Successful Treatment of Cytogenetically Normal Acute Myeloid Leukemia With Ten-Eleven Translocation 2-Isocitrate Dehydrogenase 2 and Additional Sex Comb-like 1-Nucleophosmin Co-mutations by HLA Haploidentical Stem Cell Transplantation: A Case Report and Literature Review.
Liu Y; Cao Y; Lin Y; Dong WM; Lin RR; Gu Q; Xie XB; Gu WY
Transplant Proc; 2018 Apr; 50(3):959-963. PubMed ID: 29661468
[TBL] [Abstract][Full Text] [Related]
18. Neoantigen-Specific T-Cell Immune Responses: The Paradigm of NPM1-Mutated Acute Myeloid Leukemia.
Forghieri F; Riva G; Lagreca I; Barozzi P; Bettelli F; Paolini A; Nasillo V; Lusenti B; Pioli V; Giusti D; Gilioli A; Colasante C; Galassi L; Catellani H; Donatelli F; Talami A; Maffei R; Martinelli S; Potenza L; Marasca R; Tagliafico E; Manfredini R; Trenti T; Comoli P; Luppi M
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502069
[TBL] [Abstract][Full Text] [Related]
19. Preclinical Validation of an Advanced Therapy Medicinal Product Based on Cytotoxic T Lymphocytes Specific for Mutated Nucleophosmin (NPM1
De Cicco M; Lagreca I; Basso S; Barozzi P; Muscianisi S; Bianco A; Riva G; Di Vincenzo S; Pulvirenti C; Sapuppo D; Siciliano M; Rosti V; Candoni A; Zecca M; Forghieri F; Luppi M; Comoli P
Cancers (Basel); 2023 May; 15(10):. PubMed ID: 37345068
[TBL] [Abstract][Full Text] [Related]
20. The complement receptor C3AR constitutes a novel therapeutic target in NPM1-mutated AML.
von Palffy S; Thorsson H; Peña-Martínez P; Puente-Moncada N; Sandén C; Blom AM; Henningsson R; Juliusson G; King B; Landberg N; Lazarevic V; Orsmark-Pietras C; Rissler M; Rissler V; Ågerstam H; Järås M; Lilljebjörn H; Fioretos T
Blood Adv; 2023 Apr; 7(7):1204-1218. PubMed ID: 36383712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
